MetaCap

Astrotech (DE) (ASTC) vs EyePoint (EYPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Astrotech (DE) (ASTC) has outperformed EyePoint (EYPT) over the past year, gaining 28.2% versus a loss of 98.3%. Over five years, ASTC leads with a -85.6% price change compared with -98.6% for EYPT. EyePoint is the larger company by market cap ($26.6 million vs $7.4 million), about 3.6 times the size, while Astrotech (DE) is growing revenue faster (-8.7% vs -27.5%).

EyePoint converts more of its revenue into profit, with a net margin of -739.4% versus -1580.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASTC+28.21%EYPT-98.29%
+1815%+813%-189%
Nov 21, 20251 yearNov 20, 2026
ASTC-85.77%EYPT-98.64%
+112%+2%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASTC versus EYPT key metrics
MetricASTCEYPT
Share price$3.50$0.2342
Market cap$7.45M$26.65M
1-day change-0.85%-11.36%
YTD return+1.16%-98.72%
1-year return+28.21%-98.29%
5-year return-85.60%-98.58%
EPS (TTM)$-7.88$-3.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$913.00K$31.37M
Revenue growth (YoY)-8.70%-27.50%
Net income (latest FY)$-14.43M$-231.96M
Gross margin23.77%—
Operating margin-1548.52%-775.98%
Net margin-1580.18%-739.42%
52-week high$68.85$19.11
52-week low$1.92$0.2277
Distance from 52-week high-94.92%-98.77%
Analyst consensus—buy
Avg. price target upside—+10963.19%
Average volume30.46K8.37M
Shares outstanding2.13M113.78M
Employees—214
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EyePoint is about 3.6 times larger than Astrotech (DE) by market value ($26.65M vs $7.45M).
  • ASTC has outperformed EYPT by 126.5 percentage points over the past year.
  • EyePoint is more profitable, keeping -739.4 cents of every revenue dollar as net income versus -1580.2 cents for Astrotech (DE).
  • Astrotech (DE) grew revenue faster in its latest fiscal year (-8.70% vs -27.50%).

About Astrotech (DE)

ASTC stock →

Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology.

Industrials · Biotechnology: Laboratory Analytical Instruments

About EyePoint

EYPT stock →

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.

Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees

ASTC vs EYPT FAQ

Which is bigger, Astrotech (DE) or EyePoint?

EyePoint (EYPT) is larger, with a market capitalization of $26.65M compared with $7.45M for Astrotech (DE) (ASTC).

Which stock has performed better over the past year, ASTC or EYPT?

ASTC returned +28.21% over the past 12 months, compared with -98.29% for EYPT (price return, excluding dividends). Past performance does not predict future results.

Are Astrotech (DE) and EyePoint in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons